Spectrofluorometric quantification of Clozapine in pharmaceutical formulations and human plasma
Spectrofluorometric quantification of Clozapine in pharmaceutical formulations and human plasma
분석과학 / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
2022, v.35 no.1, pp.24-31
https://doi.org/10.5806/ast.2022.35.1.24
MohammedAli Fahim(Ali Fahim Mohammed)
(Chemistry Department, College of Science, Babylon University, Medical Physics Department, Al-mustaqbal University College)
AlshirifiAN(AN Alshirifi)
(Chemistry Department, College of Science, Babylon University)
KadhimKasim Hassan(Kasim Hassan Kadhim)
(Chemistry Department, College of Science, Babylon University)
MohammedAli Fahim,
AlshirifiAN,
&
KadhimKasim Hassan.
(2022). Spectrofluorometric quantification of Clozapine in pharmaceutical formulations and human plasma, 35(1), 24-31, https://doi.org/10.5806/ast.2022.35.1.24
Abstract
Herein, we present a simple, precise, accurate, and ultra-sensitive spectrofluorimetric method for estimation of clozapine (CLZ) in tablets and human plasma was developed and then validated. A highly fluorescent brown-yellowish fluorophore was formed (λex=469 nm, λemi=540 nm) as a nucleophilic substitution reaction occurred between CLZ and 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) in alkaline mcllavine buffer (pH 9.0). Optimum values of experimental parameters were carefully determined and optimized. The calibration curve was rectilinear over the concentration range of 80-900 ng mL-1 with a linear correlation coefficient (r=0.9984). The LOD and LOQ were determined to be 14 ng mL-1 and 42 ng mL-1, respectively. The proposed approach has been used successfully to quantification of Clozapine in its commercial formulations and human plasma.
- keywords
-
clozapine,
NBD-Cl,
spectrofluorimetric,
human plasma
- 투고일Received
- 2021-10-20
- 수정일Revised
- 2021-11-03
- 게재확정일Accepted
- 2021-12-08
- 출판일Published
- 2022-02-25